Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Duke University · Fudan University · +13 more institutions
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also…
Citation impact
- FWCI
- 76.36
- Percentile
- 100%
- References
- 505
Authors
10- XBXuhui BaoCorresponding
Duke University, Fudan University, Fudan University Shanghai Cancer Center, Duke Medical Center, Pudong Medical Center, East China Normal University
- YLYongjun Liang
Fudan University, Pudong Medical Center
- HCHanman Chang
Illinois Institute of Technology, Institute for Food Safety and Health
- TCTianji Cai
University of Macau
- BFBaijie Feng
Fudan University, Pudong Medical Center
Topics & keywords
- PCSK9
- Kexin
- Proprotein convertase
- Medicine
- Alirocumab
- Cancer
- Bench to bedside
- Evolocumab
- Good health and well-being